key: cord-0683444-udjbw1lf
authors: Chang, Kai Chieh
title: Response to the letter “Does SARS-CoV-2 truly cause infectious myopathy?”
date: 2020-09-10
journal: J Formos Med Assoc
DOI: 10.1016/j.jfma.2020.08.046
sha: baf3518526b551892f7001905a79df9f8113bf1e
doc_id: 683444
cord_uid: udjbw1lf

nan

Response to the letter "Does SARS-CoV-2 truly cause infectious myopathy?" Dear Editor:

We would like to respond to the Letter "Does SARS-CoV-2 truly cause infectious myopathy?" by Finsterer and Scorza.

We would like to thank Drs. Finsterer and Scorza for their interest on our article and this phenomenon. They have raised some interesting questions about our article, especially about the actual etiology of the myopathic changes observed. First, we are aware that our reported patient received many medications that could cause pathological changes in the muscle, including hydrochloroquine, statin, and antiviral agents. However, it should be noted that despite receiving the medications early in the disease course, the patient developed general weakness and had progressive hyperCKemia after the medications are discontinued. Thus, it would be inappropriate to attribute the muscle disease to the medications. Second, although the patient had been in critical condition, this abrupt elevation and decrement of creatine kinase, along with rapid deterioration and improvement in muscle strength, are atypical for critical illness myopathy. Furthermore, beside our article, there has been other recent articles reporting presence of pathological 1 and image 2 changes in the muscles, along with rhabdomyolysis 3 and elevated creatine kinase. 4 Myopathy and elevated creatine kinase has also been reported in patients infected with other coronaviruses, such as SARS-CoV-1 5,6 and MERS-CoV. 7 Although it is difficult to prove that there is direct involvement of the skeletal muscle by SARS-CoV-2, we remained confident that it is still reasonable to assume a possible association of the myopathy with the virus e as we stated in our article e since the patient's condition could not be fully explained by known etiologies and mechanisms. Facing a novel pathogen causing a global epidemic not seen before, it is reasonable that we may encounter many novel clinical presentations and mechanisms of pathogenesis. Simply attributing them to the classical etiologies and ignoring them altogether would be a disservice to science and humankind.

The author has no conflicts of interest relevant to this article.

COVID-19 associated myositis with severe proximal and bulbar weakness

Myositis as a manifestation of SARS-CoV-2

Rhabdomyolysis as potential late complication associated with COVID-19

Early neurological manifestations of hospitalized COVID-19 patients

Neuromuscular disorders in severe acute respiratory syndrome

Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series

Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection-clinicopathological and ultrastructural study